Swallowed volumes in the fetus are greater than adult values (per body weight) and serve to regulate amniotic fluid volume. Central AngII stimulates swallowing, and nonspecific AngII receptor antagonists inhibit both spontaneous and AngII-stimulated swallowing. In the adult rat, AT1 receptors mediate both stimulated drinking and pressor activities, while the role of AT2 receptors is controversial. As fetal brain contains increased AngII receptors compared to the adult brain, we sought to investigate the role of both AT1 and AT2 receptors in mediating fetal swallowing and pressor activities. Five pregnant ewes with singleton fetuses (130±1 d) were prepared with fetal vascular and lateral ventricle (LV) catheters, electrocorticogram and esophageal electromyogram electrodes and received 3 studies over 5 days. On day 1 (AngII), following a 2 h basal period, 1 ml artificial cerebrospinal fluid (aCSF) was injected in the LV. At time 4hr, AngII (6.4µg) was injected in the LV and the fetus monitored for a final 2h. On day 3, AT1 receptor blocker (Losartan 0.5 mg) was administered at 2h, and AngII plus losartan administered at 4h. On day 5, AT2 receptor blocker (PD-123319 0.8mg) was administered at 2h, and AngII plus PD-123319 at 4h. In the AngII study, LV injection of AngII significantly increased fetal swallowing (0.9±0.1 to 1.4±0.1 swallows/min; P<0.05). In the losartan study, basal fetal swallowing significantly decreased in response to blockade of AT1 receptors (0.9±0.1 to 0.4±0.1 swallows/min; P<0.05), while central injection of AngII in the presence of AT1 receptor antagonism did not increase fetal swallowing (0.6±0.1 swallows/min). In the PD-123319 study, basal fetal swallowing did not change in response to blockade of AT2 receptor (0.9±0.1 swallows/min), while central injection of AngII in the presence of AT2 blockade significantly increased fetal swallowing (1.5±0.1 swallows/min; P<0.05). AngII caused significant pressor responses in the control and PD-123319 studies, but no pressor response in the presence of AT1
Swallowed volumes in the fetus are greater than adult values (per body weight) and serve to regulate amniotic fluid volume. Central AngII stimulates swallowing, and nonspecific AngII receptor antagonists inhibit both spontaneous and AngII-stimulated swallowing. In the adult rat, AT1 receptors mediate both stimulated drinking and pressor activities, while the role of AT2 receptors is controversial. As fetal brain contains increased AngII receptors compared to the adult brain, we sought to investigate the role of both AT1 and AT2 receptors in mediating fetal swallowing and pressor activities. blockade. These data demonstrate that in the near term ovine fetus, AT1 receptor, though not AT2 receptors accessible via CSF contribute to dipsogenic and pressor responses.
Introduction:
In the near term ovine fetus, fetal swallowing contributes importantly to amniotic fluid volume regulation and gastrointestinal tract development (20, 27, 49) . The near term ovine fetus demonstrates an intact swallowing response to central dipsogenic stimuli, including hypertonicity (41) and angiotensin II (AngII) (42) . Furthermore, tonic central AngII activity contributes to spontaneous swallowing activity, as non-selective blockade of central AngII receptors attenuated both basal as well as AngII-mediated fetal swallowing activities (16) .
In adult animals, brain derived AngII is a potent stimulant of water and sodium intake and an important regulator of blood pressure (39, 21, 53) . The recent development of specific, highly selective, nonpeptide AngII-receptor antagonists have identified two major AngII-receptor subtypes, AT1 and AT2. In adult animals of several species, neuronal AT1 receptors found in the lamina terminalis, hypothalamic paraventricular nucleus and the nucleus tractus solitarius mediate the dipsogenic, pressor and arginine vasopressin (AVP) releasing actions of AngII (13, 19, 30) .
The AT2 receptor is expressed differently from AT1 receptor, as it is found mainly in the cerebellum and thalamus (2, 3) . AT2 receptors may contribute importantly to fetal development, they are highly expressed during fetal development and expression declines rapidly after birth (28, 48) . Although little is known of the function of AT2 receptors, several (22, 23) though not all studies (8, 51) have suggested that AT2 and AT1 receptors act synergistically to augment water intake. Notably, the AT2 receptor also has been demonstrated to oppose the pressor effect of AT1 receptor stimulation (31, 44) .
The role of AngII receptor subtypes in mediating fetal swallowing and cardiovascular regulation has not been previously explored. In view of the fundamental differences in expression and localization of AT2 receptors in the fetal compared to adult brain, and the evidence that AT2 receptors may synergistically augment AT1-mediated adult drinking behavior, we sought to determine the specific roles of central AT1 and AT2 receptors in mediating spontaneous and AngII-mediated fetal swallowing as well as cardiovascular regulation.
Material and methods
Five time-dated pregnant ewes with singleton fetuses (130±1 days' gestation on the first study day) were studied. Western mixed-breed sheep were obtained from a local farm (Nebeker Farm, Palmdale, Calif). Animals were housed indoors in individual steel study cages and acclimated to a 12:12-hour light-dark cycle. Surgical procedures and studies were approved by the Harbor-University of California Los Angeles Animal Use Committee. Food (alfalfa pellets) and water were provided ad libitum, except that food was withheld for 24 hours before surgery (water was available to the animal until the time of surgery).
Surgical preparation
Anesthesia was induced with ketamine hydrochloride (15 to 20 mg/kg intramuscularly), and general anesthesia was maintained with 1% to 2% isoflurane and 1 L/min of oxygen. The uterus was exposed by a midline abdominal incision, and a small hysterotomy was performed to expose the fetal hind limb. Polyethylene catheters with inner diameters of 0.040 inch and outer diameters of 0.070 inch were placed in the fetal femoral vein and artery and threaded to the inferior vena cava and abdominal aorta, respectively. Surgical placement of bipolar electromyography (EMG) electrodes (thyrohyoid muscle and upper and lower nuchal esophagus) for determination of swallowing activity was performed. Electrodes were also implanted on the parietal dura through 2 drilled burr holes (5 mm above the bregma and 10 mm from each side of the sagittal suture) for the determination of fetal electrocortical (ECoG) activity. An 18-gauge needle connected to polyethylene catheter (inner diameter, 0.02 inch; outer diameter, 0.04 inch) was inserted into the lateral ventricle that was identified 20 mm above the lambdoid suture and 5 mm lateral to the sagittal suture. The lateral ventricle needle and the dural electrodes were immobilized with dental cement and 2 stainless steel screws fixed in the skull. An intrauterine catheter (inner diameter, 0.125 inch; outer diameter, 0.25 inch; Corometrics Medical Systems, Wallingford, Conn) was inserted for measurement of amniotic fluid pressure. Uterine and maternal incisions were repaired and all catheters and electrodes externalized to the maternal flank and placed in a cloth pouch. Catheters also were placed in the maternal femoral vein and artery. Animals were allowed at least 5 days for postoperative recovery, which included catheter maintenance and antibiotic administration (20) .
Study protocol
The study protocol was conducted over a 5-day period. The effects of central artificial cerebrospinal fluid (CSF) and AngII on fetal swallowing were examined on the first day of the study. On days 3 and 5, central effects of the selective AngII AT1 (Losartan, 0.5mg, 1 ml) and AngII AT2 (PD-123319, 0.8mg, 1ml) receptor blockers, respectively, were examined. Each experiment was separated by a minimum of 36 h of rest. Studies were initiated with the ewes standing in the same individual cages in which they were housed before the study. An equilibration period included preparation of the animals for the experiments and confirmation that fetal arterial pH was >7.30. All doses were injected slowly over 5 minutes.
Artificial CSF-angiotensin II study
Following a 2-h baseline period (time 0 to 2 hr), artificial cerebrospinal fluid (1 ml; 145 mEq/L sodium; 3.3 mEq/L potassium; 121 mEq/L calcium; 2.2 mEq/L magnesium; 121 mEq/L chloride, 25 mEq/L bicarbonate; osmolality, 297 mOsm/kgH 2 O) was injected into the lateral ventricle (ICV) and the fetuses were monitored for 2 h (from 2 to 4hr). At time 4 hr, AngII (1 ml, 6.4 µg/ml) was injected ICV and fetuses were monitored for a final 2 hours.
Losartan study
After a 2-h baseline period, losartan dissolved aCSF (0.5 mg, 1 ml; Merck, NJ,) was injected ICV. At time 4 h the dose of losartan was repeated together with AngII (1 ml, 6.4 µg) and fetuses monitored for a final 2 h.
PD-123319 study
After a 2-h baseline period, PD-123319 dissolved in normal saline (0.8mg, 1ml; Sigma, St Louis, MO) was injected ICV. At time 4 hours the dose of PD-123319 was repeated together with AngII (1 ml, 6.4 µg) and fetuses monitored for a final 2 hr.
Throughout the experiments, fetal swallowing and ECoG activities, fetal and maternal arterial blood pressures and heart rates, and amniotic fluid pressures were monitored continuously. Maternal and fetal blood samples (5 ml) were collected at hourly intervals for measurement of hematocrit, blood gases, and plasma osmolality, electrolytes and AVP. Fetal blood samples were replaced with an equivalent volume of heparinized maternal blood withdrawn before the study, and maternal blood samples were replaced with an equivalent volume of 0.15-mol/L saline solution. Five-minute segments of fetal and maternal blood pressure and heart rate data were analyzed at 1 and 2 hours (control period) and at 5, 10, 15, 30, 60, and 120 min after each drug injection.
Analytical methods
Maternal and fetal blood samples were collected into chilled iced tubes that contained 10 units/mL of lithium heparin. Blood aliquots were assessed for hematocrit, pH, P O2 , and P CO2 . The remaining blood was centrifuged and plasma osmolality, sodium, chloride, and potassium concentrations were measured. Maternal and fetal plasma aliquots were stored at -20°C until assayed for arginine vasopressin (AVP).
Blood P O2 , P CO2 , and pH were measured at 39°C with a Nova Stat 3 blood gas analyzer system (Nova Biomedical, Waltham, Mass). For the analysis of plasma AVP, the samples were collected into an ice-chilled glass tube that contained 10 IU heparin and 500 IU aprotinin per milliliter of blood. Samples were extracted by use of a modification of the procedure of LaRochelle et al (28) , and AVP levels were determined with radioimmunoassay. Plasma AVP recoveries in our laboratory average 70%.
Data analysis
Digitization of all signals was performed at a rate of 75 Hz. EMG and ECoG activity signals were directed to a Grass physiologic recorder and to a Windaq analog digital system (Dataq Instruments Inc, Akron, Ohio). An EMG-propagated swallow, representing a coordinated laryngeal-esophageal contraction, was defined by a time sequence of integrated EMG signals from the thyrohyoid muscle to the upper and lower nuchal esophagus. The time at the onset of each swallow was stored for later analysis, and swallowing activity was expressed as swallows per minute.
Fetal ECoG activity was assessed by visual analysis and was divided into periods of low voltage (LV) and high voltage. Periods of ECoG activity that did not clearly belong to either low-or high-voltage activities were considered to be intermediate ECoG activity. Intermediate ECoG activity constituted less than 5% of the total ECoG activity and was not considered in the analysis of the data. Total swallowing activity was calculated as defined earlier and was expressed as swallows per minute.
Statistical analysis
For each animal, swallowing rate per minute, percentage of time spent in each ECoG activity state, and percentage of swallowing in each state was calculated for the control and drug exposure periods. Data of fetal swallowing and all other fetal and maternal parameters were analyzed using one way repeated measure ANOVA with the Dunnett's test for post hoc analysis.
All data are presented as mean values ± SEM, and P < 0.05 was considered to be statistically significant.
Results

Control artificial CSF-angiotensin II study
ICV injection of artificial CSF did not change total fetal swallowing (0.9 ± 0.2 to 1.0 ± 0.2 swallow/min), whereas ICV injection of AngII significantly increased swallowing activity (1.4 ± 0.2 swallow/min; P < 0.05; Fig 1a) . Fetal swallowing occurred primarily during LV ECoG activity (control 1.2 ± 0.2; aCSF 1.2 ± 0.1; AngII 1.9 ± 0.4 swallow/min during LV ECoG activity; P < 0.05). Fetal swallowing during high voltage ECoG activities were (control 0.6 ± 0.1; aCSF 0.6 ± 0.1; AngII 0.8 ± 0.1 swallow/min during HV ECoG activity; P < 0.01).
The percentage of time spent in LV ECoG activity was stable during the control period (52 ± 5%), after injection of artificial CSF (52 ± 1%), and after injection of AngII (56 ± 5%; P = NS). Fetal mean blood pressure did not change after injection of artificial CSF, but it significantly increased at 15 min after ICV injection of AngII (53 ± 4 to 58 ± 3 mm Hg; P < 0.003; Fig 2a) .
Fetal heart rate increased at 5 min post ICV injection of AngII, however it achieved significance only at 30 min (170 ± 4 to 208 ± 18 beats/min; P <0.01). Fetal plasma AVP concentration increased significantly after ICV injection of AngII (0.9 ± 0.2 to 5.6 ± 2.3 pg/mL; P <0.03).
Losartan study
ICV injection of the AT1 receptor antagonist (losartan) significantly reduced total mean spontaneous fetal swallowing (0.9± 0.1 to 0.4 ± 0.1 swallow/min; P < 0.001; Fig 1b) . ICV AngII in the presence of losartan did not increase swallowing activity (0.6 ± 0.1 swallow/min; Fig 1b) . The percentage of time spent in LV ECoG activity was stable during the control period (51 ± 5%), after injection of losartan (49 ± 4%), and after injection of losartan and AngII (53 ± 6%; P = NS). Neither fetal blood pressure (49 ± 2 mm Hg ; Fig 2b) , heart rate (166 ± 3 beats/min) nor plasma AVP (2 ± 1 pg/mL) changed significantly during the study. The percentage of time spent in LV ECoG activity was stable during the control period (56 ± 1%), after injection of PD-123319 (52 ± 2%), and after injection of PD-123319 and AngII (57 ± 2%; P = NS). Fetal blood pressure did not change in response to PD-123319, but significantly increased at 5 min post ICV injection of AngII (control 51 ± 3 mm Hg; AngII 58 ± 3 mm Hg; P < 0.02; Fig. 2c ). Fetal heart rate did not change in response to P-123319 or ICV AngII. Fetal plasma AVP concentration increased significantly after ICV AngII (1.1 ± 0.5 to 5.5±2.8 pg/mL; P < 0.03).
PD-123319 study
In all study protocols, fetal hematocrit, pH, P O2 , P CO2 , plasma osmolality and sodium, chloride, and potassium concentrations values drawn at the end of the 1 st hour of the baseline period did not change (Table 1) . Similarly, maternal arterial parameters did not change from control values.
Discussion:
This study examined the roles of central AngII receptor subtypes in the regulation of fetal Losartan is highly selective for AT1 receptors with 30,000 times more selectivity to AT1 than AT2 receptors (10), while PD123319 is characterized by its high affinity for AT2 receptors with very low affinity for AT1 receptors (48) . The dose of the selective AT1 and AT2 blockers were calculated based upon rat studies (43, 52) , after adjustments for the differences in CSF volume between adult rat (~0.3 to 0.4 ml) (33) , and near-term fetal sheep (~ 7 ml) (18) . The chemical purity of both losartan and PD-123319 were checked by the manufacturers (Merck and Sigma, respectively) utilizing High Performance Liquid Chromatography.
We have used ICV PD123319 in a dose of 0.8mg. Converting this dose to nM, the concentration of PD123319 in the CSF would be 1551nM. In a study by McMullen et al (32) in pregnant ewes, PD123319 competition curve demonstrated that PD123319 achieved half maximal displacement (IC 50 ) of AngII from AT2 receptor in the uterine arteries at a concentration of 14.5 nM. In the brain tissue the IC 50 of PD123319 is 210nM (9) . Therefore our dose of PD123319 used centrally was sufficient to block more than 50% of periventricular AT2 receptors.
In agreement with our study, Weisinger et al utilizing water deprived adult sheep, found that PD-123319 ICV infusion (5000 pg/h) did not block the dipsogenic effect of ICV infusion of AngII (3.8 pg/h) (51). As PD123319 was dissolved in normal saline and we utilized aCSF in the control study (aCSF/AngII), we have utilized 3 additional control normal saline studies in which 1ml of normal saline was injected ICV after 2 hr basal periods. ICV normal saline caused no hemodynamic or biochemical changes as fetal blood pressure, heart rate, blood gases, osmolality, and chemistry did not change from basal values. Similarly fetal swallowing did not change from basal values (0.8 swallow/min).
In the adult rat (21) Other studies have demonstrated that both AT1 and AT2 blockers inhibit central AngII-induced water intake (6) and AT2 blockers (PD-123319) inhibit AngII mediated drinking only in rats, which are fed high salt diets (10) . Thus AT2 receptors may synergistically enhance AT1-mediated water intake only under special circumstances.
In accord with the high density of AT1 receptors in various brain regions involved in cardiovascular regulation in several species (35, 4, 5, 2) , the AT1 receptor contributes to adult blood pressure control. The AT1 receptor maintains resting blood pressure in anaesthetized rats on a low-salt diet, suggesting a role in maintaining resting blood pressure under conditions of increased central AngII levels (15) . In the conscious adult rat, chronic lateral ventricle infusion of AT1 antagonist significantly decreased basal blood pressure (56), suggesting that AT1 receptor in the brain plays a significant physiological role in the regulation of basal blood pressure. In conscious newborn lambs, both systemic and lateral ventricle administration of AT1 antagonist but not AT2 receptors mediate both the pressor and AVP releasing effects of central AngII.
Although AT2 blockade resulted in small rise in basal blood pressure, the variance was large and in order to detect a significant increase in basal blood pressure in response to AT2 blockade with 80% confidence, a sample size of 13 would be required.
AngII receptors situated within the dipsogenic neurons are easily accessible from the CSF compartment. In fact dipsogenic neurons from the subfornical organ (SFO) and organ vasculosum lamina terminalis (OVLT) are in direct contact with CSF. As detected with electron microscopy of neuronal composition of the SFO, axonal terminals and dendrites making direct contact with ependymal cells and CSF (40, 14) . Further studies revealed that direct ICV injection of AngII was as effective as direct tissue injection into dipsogenic sensitive sites close to the ventricles (25) .
Conversely deep sites away from the ventricles were insensitive to direct injection of AngII not crossing the ventricles, supporting the hypothesis of periventricular receptor site for angiotensin (26) .
Few studies have been published describing the ontogeny of AngII receptors (AT) in the fetal rat brain. Utilizing in situ hybridization technique, AT1 receptor mRNA subtype appears in late gestation at E19 in forebrain areas involved in fluid homeostasis and cardiovascular regulation (37) . AT2 receptor mRNA appears earlier at E13, and is strongly but transiently expressed in certain structures involved mainly in motor functions and sensory integration (38) .
In the ovine preterm fetus (gestational age 110 ± 3 days corresponding to the early third trimester of human gestational age) AT1 receptors were detected within paraventricular and supraoptic nuclei (55).
Although the precise signaling pathways and the functional roles are unclear, AT2
receptors may antagonize, under physiological conditions, several AT1-mediated actions (22, 25, 11, 1, 36) . The mechanism by which AT2 receptors inhibit AT1 function is not clear. However, stimulation of the AT1 receptor increases neuronal depolarization and firing rate (47), while AT2 stimulation results in neuronal hyperpolarization and reduced neuronal excitability (54) . Although AT2 receptors are highly expressed in fetal brain (50) they do not appear to exert antagonistic effects to either AT1-mediated drinking or pressor effects. Teleologically, the high expression of AT2 receptors in early fetal life may facilitate rapid cell turnover and differentiation by opposing the growth promoting effect of AT1 receptor (29) .
In conclusion, we report an important role for AT1 receptors in maintaining AngII 
